A Study of the Effects of Canagliflozin (JNJ-28431754) on Renal Endpoints in Adult Participants With Type 2 Diabetes Mellitus

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 5813 participants.

Also called NCT01989754

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 5,813 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01989754
  • EudraCT 2013-003050-25
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Australia, Belgium, Brazil, Canada, China, Czechia, France, Germany, Hungary, Italy, Malaysia, Mexico, Netherlands, New Zealand, Poland, Puerto Rico, Russia, South Korea, Spain, Sweden, Taiwan, Ukraine, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01989754. Randomized; quadruple masking; primary purpose treatment. Start 2014-01-16 (actual); primary completion 2017-02-23 (actual). Results posted on 2018-12-11.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of the Effects of Canagliflozin (JNJ-28431754) on Renal Endpoints in Adult Participants With Type 2 Diabetes Mellitus
Acronym
CANVAS-R
Condition
Diabetes Mellitus, Type 2
Condition
Albuminuria
Intervention (Drug)
Placebo
Intervention (Drug)
Canagliflozin, 100 mg
Intervention (Drug)
Canagliflozin, 300 mg
Lead sponsor
Janssen Research & Development, LLC (class: industry)
Collaborator
The George Institute for Global Health, Australia (class: other)

Record details

Record id
cardio:ct-nct01989754
Content hash
06b66e9e795bc702c4ca10f61ef64baee2a21fd2c603ac394b378248b6207e0a